Feb 2017 FDA Update HBV Reactivation Labeling Revisions
Shadowfax said
Feb 21, 2017
Great information. This is exactly how they followed me during TX.
Thank you
SF
Tig said
Feb 20, 2017
On February 14, 2017 FDA approved class labeling revisions regarding the risk of hepatitis B virus reactivation in patients coinfected with hepatitis C virus (HCV) and hepatitis B virus (HBV). The class labeling applies to the following HCV direct acting antiviral (DAA) agents:
Daklinza (daclatasvir)
Epclusa (sofosbuvir/velpatasvir)
Harvoni (ledipasvir/sofosbuvir)
Olysio (simeprevir)
Sovaldi (sofosbuvir)
Technivie (ombitasvir/paritaprevir/ritonavir)
Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets)
Great information. This is exactly how they followed me during TX.
Thank you
SF
On February 14, 2017 FDA approved class labeling revisions regarding the risk of hepatitis B virus reactivation in patients coinfected with hepatitis C virus (HCV) and hepatitis B virus (HBV). The class labeling applies to the following HCV direct acting antiviral (DAA) agents:
2017 FDA Update